Expression of CGRP, vasculogenesis and osteogenesis associated mRNAs in the developing mouse mandible and tibia

Yuuki Maeda, Yoko Miwa, Iwao Sato
Department of Anatomy, School of Life Dentistry at Tokyo, The Nippon Dental University Tokyo, Japan

Abstract

The neuropeptide Calcitonin Gene-Related Peptide (CGRP) is a well-characterized neurotransmitter. However, little is known about the role of CGRP in osteogenesis and vascular genesis during the developmental formation of bone. In the present study, we assessed the abundance of CGRP mRNA and the mRNA of osteogenesis and vascular genesis markers in the foetal mouse mandible and leg bone (tibia). We also analysed the expression and localization of CGRP, osteopontin (OPN) and vascular endothelial growth factor (VEGF-A) using in situ hybridization and immunohistochemical localization in the mouse mandible and tibia at embryonic days 12.5 (E12.5), E14.5, E17.5, and postnatal day 1 (P1). CGRP was clearly detected in the mandible relative to the tibia at E14.5. Hybridization using an anti-sense probe for CGRP was not detected in the mandible at P1. Hybridization with an anti-sense probe for OPN was detected at E14.5, later in the mandible and at P1 in Meckel’s cartilage. However, OPN was only detected in the tibia at E17.5 and later. The abundance of CGRP mRNA differed between the mandible and tibia. The level of vasculogenesis markers, such as VEGF-A, was similar to that of CGRP in the mandible. The levels of VEGF-A, cluster of differentiation 31 (CD31) and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) differed from that of OPN in the mandible. In contrast, the levels of VEGF-A, CD31, matrix metalloproteinase-2 (MMP-2), collagen I (Col I), collagen II (Col II) and OPN mRNA differed from E12.5 to P1 (P<0.001) in the tibia. The abundance of mRNA of CGRP and bone matrix markers (Col I, Col II, and OPN) was low at P5 in the tibia. These differences in CGRP and other mRNAs may induce a different manner of ossification between the mandible and tibia. Therefore, a time lag of ossification occurs between the mandible and tibia during foetal development.

Introduction

The neuropeptide Calcitonin Gene-Related Peptide (CGRP) is a neurotransmitter involved in vasculogenesis during muscle differentiation and organ development. CGRP first appears in the mouse at embryonic day 16.5 and localizes around blood vessels and cartilaginous bone matrix in the limbs.1 CGRP is involved in the formation and remodelling of bone, muscle, and connective tissues. During fracture healing and remodelling, CGRP regulates bone formation.3-5 Bone metabolism may be affected by nerves and by CGRP,4 which regulates osteoclasts and osteoblasts6-8 and epidermal stem cells.9,10 CGRP promotes osteogenesis in vitro11 and plays a specific role in regulating bone resorption during experimental tooth movement.12,13 It also participates in periodontal tissue regeneration, particularly alveolar bone regeneration.14 Transgenic mice expressing CGRP in osteoblasts display increased bone density during bone formation, in contrast to mice lacking CGRP expression. This phenotype indicates that osteopaenia results from decreased bone formation.15,16 A CGRP-deficient mouse model was analysed to understand the physiological role of CGRP in bone remodelling.17 Cranial neural crest-derived vascular endothelial growth factor (VEGF-A) regulates the proliferation, vascularization and ossification of cartilage and membranous bone.18-21 Calvarial and mandibular malformations were observed following the deletion of VEGF-A in neural crest cells.19,20 Mice lacking the secreted isoform of VEGF-A showed craniofacial defects including cleft palate, unfused cranial sutures, and shorter jaws.21 OPN is a major non-collagen glycoprotein in the bone matrix that regulates mineralization and bone resorption. OPN is primarily expressed in the lower hypertrophic cell zone at the site of endochondral bone formation of long bones and the cartilage matrix.22-25 Furthermore, Ichikawa et al. observed OPN-positive sensory neurons in the spinal and trigeminal ganglion.26 Moreover, insulin-like growth factor system, perlecan, dentin matrix protein, and matrix extracellular phosphoprotein affected the formation of mandibular condylar cartilage in foetal mice and humans.27-29 However, there are no reports regarding CGRP, VEGF-A, or OPN mRNA levels during mandibular bone formation. Conversely, previous studies have demonstrated a role for Meckel’s cartilage anterior to the intramembranous ossification centre during ossification of the mouse mandible.30 Receptor activator of nuclear factor-kappa B (RANKL), osteoprotegerin (OPG)31 and MMPs32 acts to degrade Meckel’s cartilage during endochondral bone formation in the mandible. Interleukin-beta also alters chondrocyte activity in Meckel’s cartilage during mandible formation.33 However, there are many events that influence Meckel’s cartilage during mandible formation. For example, CGRP in osteoblasts is a marker for increasing bone density.34 However, there are few reports on the relationship between CGRP, OPN and osteocalcin during the formation of bone under cartilage. In general, the expression of and correlation between CGRP and osteogenic markers in the developing mandible during craniofacial formation have remained unclear. Here, we use real-time PCR to quantify CGRP mRNA and the mRNA of other bone and cartilage morphological markers to differentiate between terminal mouse mandible and leg bone (tibia). Moreover, we obtained localization data on these markers using in situ hybridization levels in the two regions.

Materials and Methods

Sample preparation

All laboratory animals were procured from the Nippon Medical Science Animal Resource Laboratory and were bred at the Animal Testing Centre of the Department of Dentistry, Nippon Dental University. Male mice (Cler Japan, Inc., Tokyo, Japan) were maintained on a solid pellet diet (MF; Oriental Yeast Inc., Tokyo, Japan). The mice were used on embryonic days 12.5 (E12.5), E14.5, E17.5, and E18.5 and postnatal days 0 (P0), P1, and P5. The animals...
were sacrificed using an overdose of pentobarbital, and the right mandible and tibia were subsequently removed. Fresh samples were isolated and prepared from the right mandible and tibia from four groups. Tissue from each stage (n=4) was used for light microscopy studies and mRNA analyses using real-time RT-PCR.

**Analysis of mRNA using real-time RT-PCR**

**Isolation of total RNA**

The mandible and tibia were removed from each mouse (E12.5, E14.5, E17.5, E18.5, P0, P1 and P5) by immediately scraping after sacrifice and then storing at -80°C. The mandible and tibia were cut into small pieces, and 20-50 mg of total RNA was isolated from the samples using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. Contaminating DNA was removed using RNase-free DNase (DNA-free; Ambion, Austin, TX, USA), and the total RNA was quantified using a spectrophotometer (Biowave S2100; Cambridge, UK) at an absorbance of 260 nm. The samples were stored at -80°C until further use. Total RNA was converted to cDNA using 0.4 µM random hexamers (N808-0127; Applied Biosystems, Carlsbad, CA, USA) in a mixture containing dNTPs at 1 mM each, 20 units of RNase inhibitor (2311A; TaKaRa, Tokyo, Japan), 5 units of AMV reverse transcriptase XL (2620A; TaKaRa), 25 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM DTT, and 5 mM MgCl₂. The following thermal PCR incubation conditions were used: 30°C for 10 min, 42°C for 30 min, 90°C for 5 min, and 5°C for 5 min. We obtained separate connective tissue (50 µL) contained 100 ng of cDNA, 2.5 µL of 5× AMV reverse transcriptase XL (500 U/µL; Applied Biosystems), 500 nM forward primer, 500 nM reverse primer, 0.1% Tween-20, and 100 mM MgCl₂. The following thermal PCR incubation conditions were used: 50°C for 2 min and 95°C for 10 min, followed by 50 cycles of 95°C for 15 s and 60°C for 1 min. The following sequences were amplified: embryonic CGRP (NM00801463_g1; Applied Biosystems), VEGF-A (vascular endothelial growth factor A, NM00437304_m1, Applied Biosystems, CA, USA), PECAM (CD31), (NM01242584_m1; Applied Biosystems), anti-collagen 1 (Col I) (At02200180_g1; Applied Biosystems), anti-collagen II (Col II) (NM01305651_m1; Applied Biosystems), OPN (NM00436767_m1; Applied Biosystems), matrix metalloproteinase 2 (MMP-2) (NM004349498_m1; Applied Biosystems), and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) (NM00475056_m1; Applied Biosystems). TaqMan Rodent GAPDH Control Reagents with the VIC Probe were also used (Applied Biosystems). Levels of the amplified mouse cDNAs were normalized to those of GAPDH (roden GAPDH primers and probes were obtained from “Assays-On-Demand”, Applied Biosystems). The threshold cycle (Ct), defined as the cycle at which amplification of the PCR product enters the exponential phase, was determined for each gene by plotting the fluorescence level versus cycle number on a logarithmic scale. The relative expression levels of the genes of interest (Col I, Col II, VEGF-A, CD31, LIVE-1, MMP-2, OPN, CGRP) were estimated by calculating the ΔCt value, defined as the difference in the Ct values of the targets and the reference gene (GAPDH), according to the manufacturer’s recommendations. The ΔCt was inversely proportional to the level of each mRNA transcript present in the muscle samples from the mouse. A higher Ct value corresponded to a lower mRNA level. The levels of amplified mouse cDNAs were expressed as the quantity divided by the value of the same gene at E12.5 on the Y-axis of each graph.

**In situ hybridization**

DNA fragments of 272 bp corresponding to murine CGRP (GenBank accession number NM_001033954.3), OPN (GenBank accession number NM_0000954.1) and VEGF-A (GenBank accession number NM_000954.0) were subcloned into the pGEMT-Easy vector (Promega, Madison, WI, USA) and used for the generation of sense or anti-sense RNA probes. Paraffin embedded intestinal sections (6 µm) from E12.5, E14.5, E17.5 and P1 mice were obtained from GenoPath Co., Ltd., Tokyo, Japan. The E12.5, E14.5, E17.5 and P1 mice were dissected, fixed with Tissue Fixative (GenoPath Co., Ltd.), embedded in paraffin using the manufacturer’s proprietary procedures, and cut into 6-µm sections. The tissue sections were then de-paraffinized with xylene and rehydrated through an ethanol series and PBS. The sections were fixed 10% NBF (10% formalin in PBS) for 15 min at RT and then washed with PBS. The sections were treated with 4 µg/ml protease K in PBS for 10 min at 37°C, washed with PBS, re-fixed with 10% NBF for 15 min at RT, washed again with PBS, and placed in 0.2 N HCl for 10 min at RT. After washing with PBS, the sections were placed in 1X G-WASH (GenoPath Co., Ltd.) equal to 1X SSC. Hybridization was performed with probes at concentrations of 300 ng/ml in G-Hyb (GenoPath Co., Ltd.) for 16 h at 60°C. After hybridization, the sections were washed with 1X G-WASH for 10 min at 60°C, followed by 50% formamide in 1X G-WASH for 10 min at 60°C. Next, the sections were washed twice with 1X G-WASH for 10 min at 60°C, twice with 0.1X G-WASH for 10 min at 60°C, and twice with TBST (0.1% Tween-20 in TBS) at RT. After treatment with 1X G-Block (GenoPath Co., Ltd.) for 15 min at RT, the sections were incubated with anti-DIG AP conjugate (Roche Diagnostics, USA) diluted 1:2000 with 50X G-Block (GenoPath Co., Ltd.) in TBST for 1h at RT. The sections were washed twice with TBST and then incubated in 100 mM NaCl, 50 mM MgCl₂, 0.1% Tween-20, and 100 mM Tris-HCl, pH 9.5. Colorimetric reactions were performed with NBT/BCIP solution (Sigma-Aldrich, St. Louis, MO, USA) overnight and then washed with PBS. The sections were counterstained with Kernhecht stain solution (Muto Pure Chemicals Co., Ltd., Tokyo, Japan), and mounted with G-Mount (GenoPath Co., Ltd.). The stained sections were evaluated using microscopy (DM-2500; Leica Microsystems).

**Paraffin-embedded sections for CGRP and CD31**

CGRP and CD31 paraffin-embedded blocks for immunohistochemistry were obtained from E14.5 and E17.5 mice from GenoPath Co., Ltd. Mouse embryos were fixed with Tissue Fixative (GenoPath Co., Ltd.), embedded in paraffin using GenoPath’s proprietary procedures and cut into 6-µm sections. The tissue sections used for staining with antibody against CGRP were deparaffinized with xylene and rehydrated through a series of ethanol solutions in PBS. Endogenous peroxidases were blocked with 0.3% H₂O₂ in methanol for 30 min, followed by incubation with G-Block (GenoPath Co., Ltd.) and the use of an avidin/biotin blocking kit (Vector SP-2001, Vector Laboratories, Burlingame, CA, USA). The sections were then incubated at...
4°C overnight with rabbit polyclonal antibodies against CGRP (1 µg/mL; ENZO BML-CA1134, Cosmo Bio, Tokyo, Japan) or normal rabbit Ig (Dako X0936, Agilent Technologies, Santa Clara, CA, USA) as a negative control. The sections were washed twice with TBST for 10 min, followed by TBS for 10 min and subsequent incubation with biotin-conjugated goat anti-rabbit Ig (1:600; Dako E0432, Agilent Technologies) at room temperature for 30 min. The tissue sections to be incubated with antibodies against CD31 were deparaffinized with xylene and rehydrated through a series of ethanol solutions in PBS. Antigen retrieval was performed by microwave treatment with citrate buffer, pH 6.0. Endogenous peroxidases were blocked with 0.3% H2O2 in methanol for 30 min, followed by incubation with G-Block (Genostaff Co., Ltd.) and use of the avidin/biotin blocking kit (Vector SP-2001, Vector Laboratories). The sections were subsequently incubated at 4°C overnight with rabbit polyclonal antibody against CD31 (1 µg/mL; E1110 Spring Bioscience, Pleasanton, CA, USA) or with normal rabbit Ig as a negative control. The sections were washed twice with TBST for 10 min, followed by TBS for 10 min and subsequently incubated with biotin-conjugated goat anti-rabbit Ig (1:600; Dako E0432, Agilent Technologies) at room temperature for 30 min. After washing with TBST and TBS, the sections were incubated with peroxidase-conjugated streptavidin; Nichirei, Tokyo, Japan) at room temperature for 5 min. Peroxidase activity was visualized using diaminobenzidine. The sections were counterstained with Mayer’s Haematoxylin (MUTO Pure Chemicals Co., Ltd., Tokyo, Japan), dehydrated, and subsequently mounted with Malinol (MUTO Pure Chemicals Co., Ltd.). The stained sections were evaluated using microscopy (DM-2500; Leica Microsystems).

Statistical analysis

Differences in the quantitative real-time RT-PCR data among the groups were assessed using two-way analysis of variance (ANOVA) followed by Bonferroni’s post-hoc test with one categorical independent variable and one continuous variable (the independent variable can consist of a number of groups). The level of significance was set as P<0.05. The results are reported as the means ± SD. All statistical analyses were performed using IBM SPSS Statistics (Base, ver. 23) (New York, NY, USA).

Ethics

All procedures involving mice were reviewed and approved by the Nippon Medical Science Animal Resource Laboratory Committee of the Nippon Dental University (No. 15-31).

Results

In situ hybridization in the mandible and tibia

General observations

Haematoxylin and eosin (H&E)-stained sagittal sections of mouse heads (Figure 1 a-d, m-p) are shown at E12.5 (Figure 1 a,m), E14.5 (Figure 1 b,n), E17.5 (Figure 1 c,o) and P1 (Figure 1 d,p). Meckel’s cartilage (MC) was located in the lateral and posterior region around the condylar process of the mandible from E12.5 to P1 (Figure 1 e,l, Figure 2 a-h, and Figure 3 a-h).

In the sagittal section of the mandible at E12.5, mesenchymal cells and oral epithelial cells were aggregated, forming a cell clot. MC appeared in the mesenchymal cells of the posterior region of the mandible (Figure 1 a,e). The dental lamina appeared at E14.5, and immature bone trabeculae-like structure was also observed in the lateral-posterior region of the mandible. This immature bone trabeculae-like structure with mesenchymal cells appeared at the supra-surface and basal regions of the mandible above the immature salivary glands at E14.5 (Figure 1 b,f,j, Figure 2 b,f, and Figure 3 b f). In E17.5, bell-stage tooth germs appeared in the mandible. The immature bone trabeculae of the mandible were located at the superior, inferior and anterior regions of MC (Figure 1 g,k). At P1, numerous developed bone trabeculae-like structures appeared along with the MC in the mandible (Figure 1 d,l,n, Figure 2 d,h, and Figure 3 d,h). In contrast, at first, proximally located gathered mesenchyme cells were observed starting at E12.5, and then, chondrogenic cells were observed at E14.5 in the hind limb. In the mouse tibia, a distal developed growth plate and proximal cartilage cell zone were observed from E17.5 to P1 (Figure 1; Table 1).

In situ hybridization of CGRP

Hybridization with an anti-sense probe for CGRP was detected in numerous mesenchymal cells of both the mandible (Figure 2 a,e) and the tibia (Figure 2 l,p) at E12.5. In mesenchymal cells surrounding bone matrix, numerous mesenchymal cells at MC, Meckel’s cartilage; HC, hypertrophic cartilage; -, not detected; +, scatter; ++, concentrate; ++++, condense.

Table 1. In situ hybridization activity of CGRP, VEGF and OPN in the mandible and tibia.
matrix and blood vessels at E14.5, hybridization signals were clearly detected in the mandible (Figure 2 b,f) but not the tibia (Figure 2 m,q). mRNA for CGRP was not detected in the MC of the mouse mandible at E14.5 (Figure 2 b,f). However, mRNA for CGRP was detected in the superficial and basal regions of the mandible (Figure 2 c,g) at E17.5. Furthermore, mRNA for CGRP was not detected in the mandible (Figure 2d) at P1. In the tibia, mRNA for CGRP was clearly detected at the hypertrophic zone from E17.5 (Figure 2 n,r) to P1 (Figure 2 o,s), and no specific signals using sense probes were detected in the mandible (Figure 2 h-k) or the tibia (Figure 2 u-x).

In situ hybridization of VEGF-A

Low levels of hybridization with an anti-sense probe for VEGF-A were detected in numerous mesenchymal cells in the mandible (Figure 3 a,e) and tibia (Figure 3 m,q) at E12.5. In the mesenchymal cells and bone matrices at E14.5, cytoplasmic positivity for the hybridization signals was observed in the mandible (Figure 3 b,f). However, almost no localized signal was detected in the tibia (Figure 3 n,r). mRNA for VEGF-A was also not detected at the MC of the mouse mandible at E14.5 (Figure 3 c,g). In contrast, mRNA for VEGF-A was detected in numerous mesenchymal cells around MC and bone matrices in the mandible at E17.5 (Figure 3 c,g). mRNA for VEGF-A was also not detected in the MC of the mouse mandible at E17.5 (Figure 3 c,g).

In situ hybridization of OPN

Hybridization with an anti-sense probe for OPN was detected in numerous mesenchymal cells around the bone matrices and MC in the mandible at E14.5 (Figure 4 b,e).
Figure 2. Expression of CGRP mRNA based on in situ hybridization with an anti-sense (a-g, l-o) and a sense (h-k, t-w) probe in mouse heads at E 12.5 (a,e,h), E14.5 (b,f,i), E17.5 (c,g,j) and P1 (d,k) and tibias at E 12.5 (l,p,t), E14.5 (m,q,u), E17.5 (n,r,v) and P1 (o,s,w). The CGRP reaction was localized in (c) and (g) (arrowheads); the CGRP reaction was scattered in (f,r,s) (arrowheads). e) Magnification of the squared region in (a); f) magnification of the squared region in b); g) magnification of the squared region in (c); h) magnification of the squared region in (l); i) magnification of the squared region in (m); j) magnification of the squared region in (n); k) magnification of the squared region in (o). Mad, mandible; BT, bone trabecula-like matrices; MC, Meckel’s cartilage; DG, dental germ; TI, tibia; HC, hyaline cartilage. Scale bars: 100 μm. a-d, h-o, t-w) magnification: 10x; e-g, p-s) magnification: 40x.
Figure 3. Expression of VEGF-A mRNA based on in situ hybridization with an anti-sense (a-h, m-t) and a sense (i-l, u-x) probe in mouse heads at E 12.5 (a,e,i), E14.5 (b,f,j), E17.5 (c,g,k) and P1 (d,h,l) and tibias at E 12.5 (m,q,u), E14.5 (n,r,v), E17.5 (o,s,w) and P1 (p,t,x). The VEGF-A reaction was localized in (g,h,s,t) (arrowheads); the VEGF-A reaction was scattered in (f,g,r) (arrowheads). e) Magnification of the squared region in (a); f) magnification of the squared region in (b); g) magnification of the squared region in (c); h) magnification of the squared region in (d); i) magnification of the squared region in (m); j) magnification of the squared region in (n); k) magnification of the squared region in (o); l) magnification of the squared region in (p). Mad, mandible; BT, bone trabecula-like matrices; MC, Meckel’s cartilage; TI, tibia; HC, hyaline cartilage. Scale bars: 100 µm. a-d, i-p, u-x) magnification: 10x; e-h, q-t) magnification: 40x.
Figure 4. Expression of OPN mRNA based on *in situ* hybridization with an anti-sense (a-g, n-q) and a sense (h-k, r-u) probe in mouse heads at E 12.5 (a,h), E14.5 (b,e,i), E17.5 (c,f,j) and P1 (d,g,k) and tibias at E 12.5 (l,r), E14.5 (m,s), E17.5 (n,p,t) and P1 (o,q,u). The reaction of OPN was localized in all reaction plates (arrowheads). e) Magnification of the squared region in (b); f) magnification of the squared region in (c); g) magnification of the squared region in (d); p) magnification of the squared region in (n); q) magnification of the squared region in (o). Mad, mandible; BT, bone trabecula-like matrices; MC, Meckel's cartilage; TI, tibia; HC, hyaline cartilage. Scale bars: 100 µm. a-d, h-o, r-u) magnification: 10x; e-g, p,q) magnification: 40x.
The mRNA for OPN was detected around the bone matrices in the mandible at E17.5 (Figure 4 c,f). The mRNA for OPN was strongly detected at P1 around the bone matrices and some chondrocyte cells of the MC in the mandible (Figure 4 d,g). Moreover, the mRNA for OPN was clearly observed in the hypertrophic zone of the tibia at E17.5 and P1 but not at E12.5 and E14.5 (Figure 4 l-q), and no specific signals using sense probes were detected in the mandible (Figure 4 h-k) or the tibia (Figure 4 r-u).

**Immunohistochemistry for CGRP and CD31 in the mandible and tibia**

At E17.5, the anti-CGRP antibody revealed a slight positive reaction in mesenchymal cells in the bone trabeculae-like structures of the mandible; by contrast, in the tibia, a positive reaction was observed in numerous chondrocytes (Figure 5 a,b,d,e). The anti-CD31 antibody reaction was primarily observed in the mesenchymal cells surrounding the MC of the mandible and subsequently in the hyaline cartilage of the tibia at E14.5 (Figure 5 g,h,i,j,k).

![Figure 5. Immunohistochemical staining for anti-CGRP in sagittal sections of E17.5 mice and for anti-CD31 in sagittal sections of E14.5 mice. Positive anti-CGRP reactions (a,b,d,e) and negative controls (c,f) in mouse head at E17.5 (a-c) and tibia at E17.5 (m-s). Positive anti-CD31 reactions (g,h,i,j,k) and negative controls (i,l) in mouse head at E14.5 (g-i) and tibia at E14.5 (j-l). The reactions of CGRP and CD31 were observed through immunohistochemical localization in all reaction plates (arrowheads). b) Magnification of the squared region in (a); e) magnification of the squared region in (d). Mad, mandible; BT, bone trabecula-like matrices; MC, Meckel's cartilage; TI, tibia; HC, hyaline cartilage. Scale bars: 100 µm. a,c,d,f) magnification: 10x; b,e) magnification: 40x.](image-url)
Quantification of mRNA abundance in the mandible and tibia using real-time RT-PCR

The abundance of VEGF-A, CD31, MMP-2, CGRP, Col I, Col II, LYVE-1, and OPN mRNA in the mouse mandible and tibia at 7 different stages ranging from E12.5 to P5 is shown in Figure 4 a-h. The abundance of CGRP mRNA gradually decreased from E12.5 to E17.5 and then remained almost constant from P0 to P5 in the mandible (P<0.001). In contrast, the CGRP mRNA levels in the tibia gradually increased from E12.5 to E17.5 and then decreased at P5. Different levels of CGRP mRNA in the mandible and tibia were observed at E14.5 and E17.5 (P<0.001) (Figure 6a).

The levels of Col I, Col II and OPN mRNA gradually increased in the mandible...
from E12.5 to P5 (P<0.001), with the exception of Col II at E14.5. The abundance of CD31, MMP2 and LYVE-1 mRNAs remained constant in the mandible from E12.5 to P5, while the levels of VEGF-A were low during this time period. The levels of VEGF-A, CD31, MMP-2, Col I, Col II and OPN mRNA gradually increased in the tibia from E12.5 to P1 (P<0.001). However, the levels of these mRNAs were low at P5, and Col I was also low at P1. Furthermore, different levels of Col I, Col II, and OPN mRNA were observed between the mandible and the tibia at P5 (P<0.001) (Figure 6 e,f,h).

Discussion

CGRP first appears in mouse at E16.5, localizes around blood vessels and is closely opposed to the cartilaginous bone matrix in the limb. Here, we initially detected the anti-sense probe for CGRP in numerous mesenchymal cells of the tibia at E12.5 and then clearly detected it in both the mandible and tibia at E14.5. The appearance of the ossification centre occurs earlier in the mandible than in the human limb. Moreover, our *in situ* hybridization faintly detected CGRP in the chondroblasts of the MC and numerous mesenchymal cells around the MC. Additionally, we clearly observed CGRP mRNA in the mesenchymal cells around the blood vessels and immature bone matrices of the developing mouse mandible at E14.5. CGRP mRNA was clearly detected using *in situ* hybridization in the numerous mesenchymal cells of the tibia at E12.5. Based on these results, CGRP expression regulates bone matrix formation between E12.5 and E17.5 in mandibular bone and tibia. In contrast, the expression of CGRP mRNA is detectable in neuronal cells near trabecular bone structures, and components of the CGRP receptor are expressed in differentiated osteoblast cultures. Here, CGRP hybridization with the anti-sense probe was clearly detected in the osteoblast-like cells surrounding the blood vessels in immature bone matrices. These results are consistent with those of a previous study showing that CGRP expression is associated with blood vessels during the formation of the mouse masseter muscle. In the present study, during bone matrix formation, CGRP expression around the blood vessels started at E14.5 in the mandible and E17.5 in the tibia. In general, CGRP is widely distributed in the bone tissue and regulates bone remodelling through blood vessels around bone cells during growth and repair. CGRP-deficient mice present with low trabecular bone volume, a small number of trabeculae, and large trabecular spacing. Therefore, CGRP may be a primary regulator of OPN and of key bone matrix markers in the development of mandibular and tibia trabeculae and bone volume. In the present study, CGRP mRNA was detected at E12.5 and then decreased during development. In contrast, OPN and Col I gradually increased from E12.5 to E17.5 in the mouse mandible, but not the tibia. Under treatment with CGRP and osteocalcin, mRNAs were increased in a coculture system. CGRP plays a role in the initial steps of trabecular bone formation, as it regulates OPN and Col I. Subsequently, OPN leads to the development of trabecular bone mineralization during the membranous ossification stage of bone formation. The results of the present study further revealed that the different levels of CGRP, OPN and Col I mRNA indicated a different mechanism of mandible formation compared to tibia formation with regards to membranous and/or cartilaginous ossification. Notably, OPN mRNA was clearly detected at the trabecular bone starting at E17.5 and then appeared at detectable levels in the mandible MC through *in situ* hybridization. Thus, there are different systems regulating early bone formation and metabolism between the mandible and tibia. The vertebrate skeleton and mandible are primarily derived from the mesoderm during development; however, the formation of this bone is different from that of skeletal bone and orofacial bone, which are derived from somites and branchial arches. The mandible originates from intramembranous and endochondral tissues, unlike the tibia, which originates from endochondral tissues.

VEGF-A is essential to support blood vessel growth in the developing jaw, which in turn is essential for normal chondrocyte proliferation and therefore jaw extension. Cranial neural crest cell-derived VEGF-A regulates proliferation, vascularization and ossification of cartilage and membranous bone. Additionally, VEGF-A regulates the growth of the mandibular artery, leading to extension of the MC. In contrast, VEGF-A stimulates intramembranous bone formation in the mouse mandible despite a lack of regulated bone ossification in the normal mandible. In general, strong VEGF-A expression was observed in human glenoid fossa in cases of malformation and dermal–hypodermal derivation. Our results indicated that the localized CGRP expression was similar to that of VEGF-A expression during tibia and mandible ossification. Moreover, a positive reaction for anti-CGRP antibody was detected in mesenchymal cells in the bone trabeculae-like structures of the mandible at E17.5 and then in the hyaline cartilage of the tibia at E14.5. CGRP may regulate VEGF-A expression, and subsequently VEGF-A may be upregulated as an intermediate pathway for vascular endothelial cells and induced CD31. Therefore, a time lag of expression was observed between the mandible and tibia during foetal development. These results also showed that the pattern of OPN hybridization with the anti-sense probe was similar to that of CGRP in the tibia and mandible. In general, CGRP regulates the formation of bone. Therefore, CGRP and OPN may contribute to bone formation during the developmental stages we investigated here. At 12.5 days of age, the expression level of each factor is low, and bone element factors, such as OPN and Col I,
increased in bone matrices, but no changes in factors other than these two markers were observed in the mandible and tibia. However, the mRNA expression level of vascularogenesis markers differed between the mandible and tibia, and the localization of VEGF-A and CGRP mRNA expression shown using in situ hybridization clearly differed over the time course. Indeed, the localization of VEGF-A and CGRP mRNAs was first weakly detected and then spread throughout the blood vessels, affecting osteoblasts and the surrounding connective tissue, ultimately further changing the mesenchymal cells around the MC of mandible at the examined stages. However, we did not observe the expression of these markers at the protein level, and previous studies have reported that these markers are actually synthesized in conjunction with mRNA expression. Thus, in the present study, we observed general markers with established factors in bone formation between the mandible and tibia at the mRNA level.

Yuodelis suggested that the MC contributes to the length and width of the mandible and to masticatory muscle and jaw movement in the human temporomandibular joint. The intramembranous ossification centre appears anterior to the mandible, thereby associating the role of MC with ossification of the mouse mandible. Ishizeki et al. indicated that the posterior portion of MC is involved in rodent bone formation. In contrast, based on immunohistochemical analysis of RANKL, OPG and MMP distribution, MC does not regulate the formation of the mouse mandible. CGRP is a marker of osteoblasts, and CGRP mRNA is observed in chondroblasts of MC. Here, we observed low levels of CGRP mRNA in the chondrocytes of MC at E14.5 and E17.5 but not P0. Moreover, OPG mRNA was initially detected in the posterior region of the MC at P1 in the mouse mandible. Therefore, CGRP may regulate MC calcification starting at early postnatal stages. CGRP was also detected in mesenchymal cells of immature bone matrices and blood vessels. Therefore, CGRP likely regulates the formation of the mandible through calcification of MC.

References
25. Shibata S, Fukada K, Suzuki S, Ogawa T, Yamashita Y. In situ hybridization and immunohistochemistry of bone


34. Sperber GH. Craniofacial embryogenesis and development. J. Wright & Sons, Bristol, UK; 1976; pp. 147-159.
